The Swiss biotech sector continued to grow in 2016. It can look back on a positive year, and with a full product
pipeline, the future looks bright as well. In addition to facts and figures about the sector, this year's edition
of the Swiss Biotech Report[pdf] deals with rising
complexity in the industry and how this can be seen as an opportunity.
Reducing complexity as a function of strategy
The call for «clarity» has never been louder. Companies that master a structured approach
to reduce complexity will unlock new opportunities and successfully manage the ever-growing list of regulations.
Andrea von Bartenwerffer, Head Account Management Issuer Relations, and Christian Geiger, Relationship Manager
Issuer Relations at SIX Swiss Exchange, talk with managers of listed companies about complexity and how to pare
it down as part of their corporate strategy.
Ronald Scott, CEO of Basilea Pharmaceutica, Chris Tanner,
Head Transaction Office and Head Investor Relations at Cosmo Pharmaceuticals, Stefan Weber, CEO of Newron,
and Marc Klingelfuss, Deputy Head Corporate Finance at Bank Vontobel, explain which business divisions are the most complex, how to streamline them and how,
based on their experience, an IPO can bring clarity. They also discuss whether growth and complexity necessarily
go hand in hand in the biotech sector.
The new report was presented at this year's Swiss Biotech Day,
the leading Swiss biotechnology conference.
Europe's leading exchange for Life Sciences
SIX Swiss Exchange is Europe's leading exchange
for Life Sciences companies, representing around 40% of the European Life Sciences
market capitalization across Europe's major stock exchanges. SIX Swiss Exchange offers both Swiss and foreign
companies an ideal environment for raising capital. To learn more about our advantages for equity issuers, you
can watch our film or read our
Show all news